Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NeXstar Pharmaceuticals
Boulder, CO, United Statesnexstar.com ↗
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
At the time of its acquisition by Gilead Sciences in mid‑1999, NeXstar had two commercial products—AmBisome® for serious fungal infections and DaunoXome® for Kaposi’s Sarcoma—and a robust pipeline including MiKasome®, NX1838 for macular degeneration, NX211 for oncology indications, as well as oligonucleotide therapeutics. Its clinical programs spanned from preclinical through Phase III trials.[1][5][6]
- Therapeutic areas
- OphthalmologyOncologyImmunologyInfectious Diseases
- Modalities
- Liposomal drug formulations (liposomes)Small molecules (e.g., daunorubicin citrate, amphotericin B)Oligonucleotides[9]
- Industry
- Biotech
02
Partnerships
Notable licensing/collaboration with Glaxo Wellcome on lurtotecan liposomal development; partnerships with academic centers such as Erasmus MC noted in trial sponsorships.[7][10]
Beyond the preview
Go deeper on NeXstar Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeXstar Pharmaceuticals.